BioAge, IPO
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M. Read more here/
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA.
Drugmaker seeks $157.5M in IPO, placement
BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18.
BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment
BioAge Labs, Inc. is seeking $100 million in an IPO to fund its clinical trials for obesity and insulin sensitivity treatments. The company’s lead drug, Azelaprag, is in Phase 2 trials.
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, California-based company will join several biotech firms listing their shares this year.
Obesity drugmaker BioAge targets $158 million in IPO
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday
pharmaphorum2d
Respiratory biotech Upstream joins Nasdaq IPO surge
queue amid a flurry of IPO activity in the sector, with three biotechs listing on the Nasdaq last week – Bicara ...
BioSpace16d
Lilly Partner BioAge Files for IPO to Advance Obesity Candidate
BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...
Capital Markets
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
Hosted on MSN16d
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs filed confidentially on May 31, 2024. Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
Benzinga.com16d
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
The company's lead drug Azelaprag has been well-tolerated in 265 individuals across eight Phase 1 trials. The STRIDES clinical trial will assess azelaprag with Eli Lilly's Zepbound, with topline ...